Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials

Animal models and observational human data indicate that complement, including C5a, pathogenically participates in ischemia reperfusion (IR) injury that manifests as delayed graft function (DGF) following deceased donor kidney transplantation. We report on the safety/efficacy of anti-C5 monoclonal a...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Bernd Schröppel, Enver Akalin, Mukta Baweja, Roy D. Bloom, Sander Florman, Michael J. Goldstein, Brandy Haydel, Donald E. Hricik, Sanjay Kulkarni, Matthew H. Levine, Anita Mehrotra, Anup Patel, Emilio D. Poggio, Lloyd E. Ratner, Ron Shapiro, Peter S. Heeger
Materyal Türü:	Artigo
Dil:	İngilizce
Baskı/Yayın Bilgisi:	2019
Online Erişim:	https://doi.org/10.1111/ajt.15580 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajt.15580
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

İlk yorumlayan siz olun!

Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials

Benzer Materyaller